Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →More from Pertuza
Other strengths and forms by Incepta Pharmaceuticals Ltd.
Indications & Uses
Pertuza is indicated for:
Pharmacology
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). By binding this domain, Pertuzumab blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4. As a result, Pertuzumab inhibits ligand-initiated intracellular signaling through two major signal pathways: mitogen-activated protein (MAP) kinase, and phosphoinositide 3-kinase (PI3K). Inhibition of these signaling pathways can result in cell growth arrest and apoptosis, respectively. In addition, Pertuzumab mediates antibody-dependent cell-mediated cytotoxicity.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage
For intravenous infusion only; it should not be given as an intravenous push or bolus. The initial Pertuzumab dose is 840 mg, given as a 60 minute intravenous infusion, followed every 3 weeks thereafter by 420 mg given as a 30 to 60 minute intravenous infusion.
Metastatic breast cancer: Pertuzumab should be given together with Trastuzumab and Docetaxel by intravenous infusion every 3 weeks.
Neoadjuvant use: Pertuzumab should be given together with Trastuzumab and Docetaxel by intravenous infusion before surgery, every 3 weeks, for 3 to 6 cycles.
Pediatric use: The safety and effectiveness of Pertuzumab have not been established in pediatric patients.
Side Effects
Left ventricular dysfunction: Perjeta can lead to heart problems, both those you can't see on a test yet (subclinical) and those that are obvious (clinical). These can show up as congestive heart failure (CHF) or as a drop in LVEF. Your heart function should be checked before you start treatment and again while you are on it. If a clear, clinically significant fall in left ventricular function is confirmed, Perjeta treatment should be stopped. Embryo-fetal toxicity: Perjeta exposure can cause death of the embryo or fetus and birth defects. In animal studies it led to oligohydramnios, delayed kidney development, and death. Patients should be told about these risks and about the need for effective contraception. Metastatic breast cancer: When Perjeta is given with trastuzumab and docetaxel, the most common side effects (in more than 30% of patients) are diarrhea, hair loss (alopecia), low neutrophil count (neutropenia), nausea, tiredness (fatigue), rash, and nerve damage in the hands and feet (peripheral neuropathy). Neoadjuvant treatment of breast cancer: With Perjeta, trastuzumab and docetaxel, the most common side effects (in more than 30% of patients) are hair loss (alopecia), diarrhea, nausea, and neutropenia. When the same combination is given for 3 cycles after 3 cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC), the most common side effects (in more than 30% of patients) are fatigue, hair loss (alopecia), diarrhea, nausea, vomiting, and neutropenia. With Perjeta, docetaxel, carboplatin, and trastuzumab (TCH), the most common side effects (in more than 30% of patients) are fatigue, hair loss (alopecia), diarrhea, nausea, vomiting, neutropenia, low platelet count (thrombocytopenia), and anemia.
Cautions & Contraindications
Warnings & Precautions
Left Ventricular Dysfunction: Heart pumping function (LVEF) should be monitored, and doses should be withheld as needed. Embryo-Fetal Toxicity: This medicine can harm the developing embryo or fetus if given to a pregnant woman. Infusion-Related Reactions: Patients should be watched for signs and symptoms during infusion. If a significant infusion-related reaction occurs, the infusion should be slowed or stopped and suitable medical treatment given. Hypersensitivity Reactions/Anaphylaxis: Patients should be watched for signs and symptoms. If a severe hypersensitivity reaction or anaphylaxis occurs, the infusion should be stopped immediately and suitable medical treatment given.
Contraindications
Pertuzumab should not be used in anyone with a known hypersensitivity to pertuzumab itself or to any of the excipients in the formulation.
Pregnancy & Breastfeeding
Pregnancy Category D. There are no adequate and well-controlled studies of Pertuzumab in pregnant women. If Pertuzumab is given during pregnancy, or if a patient becomes pregnant while receiving Pertuzumab or within 7 months after the last dose of Pertuzumab combined with Trastuzumab, she should be informed of the potential risk to the fetus.
Lactation: It is not known whether Pertuzumab passes into human breast milk, though human IgG does pass into breast milk. Since many drugs are secreted in breast milk and there is a potential for serious adverse effects in nursing infants from Pertuzumab, a decision should be made on whether to stop nursing or stop the drug, taking into account the elimination half life of Pertuzumab and how important the drug is to the mother.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Storage
Keep Pertuzumab vials in a refrigerator at 2°C to 8°C until you are ready to use them. Leave each vial in its outer carton so the light doesn't reach it.
Common questions about Pertuza 420 mg/14 ml
What is Pertuza 420 mg/14 ml IV Infusion?
Pertuza 420 mg/14 ml IV Infusion is a medicine that contains Pertuzumab. It is made by Incepta Pharmaceuticals Ltd. It belongs to the Targeted Cancer Therapy group of medicines.
What is Pertuza used for?
Pertuza is used for: Cancer.
What are the side effects of Pertuza?
Left ventricular dysfunction: Perjeta can lead to heart problems, both those you can't see on a test yet (subclinical) and those that are obvious (clinical). These can show up as congestive heart failure (CHF) or as a drop in LVEF.
Can I take Pertuza during pregnancy or while breastfeeding?
Pregnancy Category D. There are no adequate and well-controlled studies of Pertuzumab in pregnant women. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Pertuza?
Keep Pertuzumab vials in a refrigerator at 2°C to 8°C until you are ready to use them. Leave each vial in its outer carton so the light doesn't reach it.
Do I need a prescription for Pertuza?
Pertuza is a prescription (Rx) medicine. Take it as your doctor advises.